C3 Glomerulopathy: Understanding Kidney Impact, Symptoms, Diagnosis, and Treatment

C3 glomerulopathy (C3G) is a rare kidney disease caused by dysregulation of the alternative complement pathway. It includes two subtypes: Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN).

Mechanism

Uncontrolled complement activation → C3 fragments deposit in glomeruli → inflammation → capillary wall damage → protein leakage → scarring → kidney failure.

Symptoms

  • Hematuria (blood in urine—often microscopic)
  • Proteinuria (foamy urine)
  • Edema (face, ankles, legs)
  • Hypertension
  • Fatigue, nausea (uremia in advanced stages)
  • Decreased urine output

Diagnosis

  • Urinalysis + urine protein:creatinine ratio
  • Blood work: creatinine, eGFR, complement levels (low C3, normal C4 = alternative pathway)
  • Kidney biopsy: Gold standard. Shows C3-dominant deposits on immunofluorescence; electron microscopy distinguishes DDD (dense ribbons) vs. C3GN (granular)
  • Genetic testing: CFH, CFI, CFB, C3, CFHR5, DGKE mutations; autoantibodies (C3 nephritic factor)

Treatment

  1. Supportive (all patients): ACEi/ARB (reduce proteinuria, BP), SGLT2 inhibitors (kidney + heart protection), statin, blood pressure control (<130/80), low-sodium diet
  2. Immunosuppression: MMF + steroids (first-line for progressive disease); rituximab, eculizumab (anti-C5), ravulizumab, iptacopan (factor B inhibitor—emerging)
  3. Complement-targeted therapies: Clinical trials (pegcetacoplan, danicopan, avacopan)
  4. Kidney replacement: Dialysis or transplant. Recurrence in transplant ~50% (DDD > C3GN). Pre-emptive complement inhibition may reduce recurrence.

Complications

  • CKD progression → ESRD (50% at 10 years)
  • Cardiovascular disease (accelerated by CKD + inflammation)
  • Infections (from immunosuppression)
  • Thrombotic risk (complement dysregulation)

Monitoring

  • Every 3–6 months: eGFR, UPCR, BP, complement levels
  • Annual: lipid panel, glucose, bone health, vaccine status

Early diagnosis, complement profiling, and multidisciplinary care (nephrology, genetics, transplant) improve outcomes. Clinical trial enrollment encouraged.

Kidney Disease - Related Articles